ATE417050T1 - Verbindungen als semaphorininhibitoren - Google Patents

Verbindungen als semaphorininhibitoren

Info

Publication number
ATE417050T1
ATE417050T1 AT03731824T AT03731824T ATE417050T1 AT E417050 T1 ATE417050 T1 AT E417050T1 AT 03731824 T AT03731824 T AT 03731824T AT 03731824 T AT03731824 T AT 03731824T AT E417050 T1 ATE417050 T1 AT E417050T1
Authority
AT
Austria
Prior art keywords
compounds
semaphorin
independently hydrogen
semaphorin inhibitors
inhibitors
Prior art date
Application number
AT03731824T
Other languages
English (en)
Inventor
Kazuo Kumagai
Nobuo Hosotani
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE417050T1 publication Critical patent/ATE417050T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • C07D311/84Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86Oxygen atoms, e.g. xanthones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT03731824T 2002-01-24 2003-01-22 Verbindungen als semaphorininhibitoren ATE417050T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002015216 2002-01-24

Publications (1)

Publication Number Publication Date
ATE417050T1 true ATE417050T1 (de) 2008-12-15

Family

ID=27606106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731824T ATE417050T1 (de) 2002-01-24 2003-01-22 Verbindungen als semaphorininhibitoren

Country Status (7)

Country Link
US (1) US7642362B2 (de)
EP (1) EP1475382B1 (de)
JP (3) JP4549675B2 (de)
AT (1) ATE417050T1 (de)
DE (1) DE60325172D1 (de)
ES (1) ES2316763T3 (de)
WO (1) WO2003062243A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4820170B2 (ja) * 2003-12-05 2011-11-24 大日本住友製薬株式会社 虚血性神経障害治療又は予防剤
CN103379906B (zh) * 2011-02-25 2016-01-20 学校法人庆应义塾 用于角膜感觉神经损伤的包含脑信号蛋白抑制剂作为活性成分的治疗剂
TWI744275B (zh) * 2016-01-15 2021-11-01 日商大日本住友製藥股份有限公司 2環性雜環化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506202A (ja) * 1991-03-22 1994-07-14 ゼノバ リミテッド 医薬用キサントン誘導体
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5416197A (en) * 1993-10-15 1995-05-16 Trustees Of The University Of Pennsylvania Antibodies which bind human collapsin
JP4108755B2 (ja) 1996-09-11 2008-06-25 大日本住友製薬株式会社 新規セマフォリン遺伝子:セマフォリンy
EP0945505A4 (de) 1996-10-09 2002-11-27 Sumitomo Pharma Neues semaphorin-gen: semaphorin w
WO2002009756A1 (en) 2000-07-28 2002-02-07 Sumitomo Pharmaceuticals Company, Limited Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient

Also Published As

Publication number Publication date
US20050119334A1 (en) 2005-06-02
ES2316763T3 (es) 2009-04-16
JP2011046734A (ja) 2011-03-10
JPWO2003062243A1 (ja) 2005-05-19
EP1475382A1 (de) 2004-11-10
JP4549675B2 (ja) 2010-09-22
WO2003062243A1 (en) 2003-07-31
JP2010013480A (ja) 2010-01-21
DE60325172D1 (de) 2009-01-22
EP1475382A4 (de) 2005-05-11
EP1475382B1 (de) 2008-12-10
US7642362B2 (en) 2010-01-05

Similar Documents

Publication Publication Date Title
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
MY132698A (en) Herbicidal composition
TNSN08174A1 (en) Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders
WO2005040116A3 (en) Indolinone derivatives and their use in treating disease-states such as cancer
MXPA05009985A (es) Ligandos de receptores de canabinoides.
BR0314688A (pt) Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina
EP1704856A4 (de) Proteininhibitor der hsp90-familie
EP1674452A4 (de) Neues 4-phenylaminobenzaldoximderivatie und dessen verwendung als mek-inhibitor
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
DE60027144D1 (de) Hydroxamsäure-derivate
EP1314712A4 (de) Substituierte benzoesäurederivate als nf-kappa-b-inhibitoren
ATE278661T1 (de) Anthranilsäurederivate
DK0903347T3 (da) Hidtil ukendte cyclodepsipeptid PF1022-derivater
MXPA05006450A (es) Nuevo derivado de 2,4-diamino-1,3,5-triazina.
UA96149C2 (en) Method for producing 4-oxoquinoline compound
EP1191022A4 (de) Neuartige dihydropyridin-derivate
ATE417050T1 (de) Verbindungen als semaphorininhibitoren
IL157440A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
ATE206125T1 (de) Furoindolizine
NO20051028L (no) Substituerte tiaziner som materialbeskyttelsesmidler
NO20065789L (no) Cinnamidforbindelse
NO20053208L (no) Metode for reduktiv dehalogenering.
ATE382607T1 (de) Antitrombotische aether
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
BRPI0406990A (pt) Derivado de oligossacarìdeo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties